Close Menu

NEW YORK (GenomeWeb News) – Asterand said today that it will validate and characterize antibodies and immunohistochemistry applications for antibody marketer Abcam.

Under the collaborative agreement, Asterand will use its PhaseZero Human Tissue Services platform and its Target Evaluator gene expression database to select antibodies and to identify expression patterns for their use with human tissue.

The resulting data will be incorporated into Abcam’s literature and technical support documentation for each antibody tested and will be sold through its online catalogue.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.